First in Human of Single and Multiple Doses of MOR106

NCT02739009 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

81

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy
Dermatitis, Atopic

Interventions

DRUG: MOR106 single ascending doses, intravenous
DRUG: Placebo single ascending doses, intravenous
DRUG: MOR106 multiple ascending doses, intravenous
DRUG: Placebo multiple intravenous administrations

Sponsor

Lakefront Biotherapeutics NV

Collaborators

[object Object]